Last reviewed · How we verify

Etrynit — Competitive Intelligence Brief

Etrynit (propatylnitrate) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vasodilators Organic Nitrates. Area: Hematology.

unknown Vasodilators Organic Nitrates Hematology Live · refreshed every 30 min

Target snapshot

Etrynit (propatylnitrate). Etrynit works by releasing nitric oxide, which relaxes blood vessel muscles and causes blood vessels to dilate.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Etrynit TARGET propatylnitrate unknown Vasodilators Organic Nitrates

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vasodilators Organic Nitrates class)

  1. · 5 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Etrynit — Competitive Intelligence Brief. https://druglandscape.com/ci/propatylnitrate. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing